EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

M. Forster; Matthew Krebs; Margarita Majem; J. Peguero; Tonya Clay; E. Felip; Wade Iams; Patricia Roxburgh; B. Doger; P. Bajaj; J. Kefas; J.-.A. Scott; Andrés Barba Joaquín; C. Mueller; F. Triebel

doi:10.1016/j.jtho.2022.07.681

EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

M. Forster, Matthew Krebs, Margarita Majem, J. Peguero, Tonya Clay, E. Felip, Wade Iams, Patricia Roxburgh, B. Doger, P. Bajaj, J. Kefas, J.-.A. Scott, Andrés Barba Joaquín, C. Mueller, F. Triebel

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S395
Journal	Journal of Thoracic Oncology
Volume	17
DOIs	https://doi.org/10.1016/j.jtho.2022.07.681
Publication status	Published - 1 Sept 2022

Access to Document

10.1016/j.jtho.2022.07.681

Cite this

Forster, M., Krebs, M., Majem, M., Peguero, J., Clay, T., Felip, E., Iams, W., Roxburgh, P., Doger, B., Bajaj, P., Kefas, J., Scott, J.-A., Barba Joaquín, A., Mueller, C., & Triebel, F. (2022). EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC. Journal of Thoracic Oncology, 17, S395. https://doi.org/10.1016/j.jtho.2022.07.681

@article{e5077318de1e40d7abe765ed87b29e3b,

title = "EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC",

author = "M. Forster and Matthew Krebs and Margarita Majem and J. Peguero and Tonya Clay and E. Felip and Wade Iams and Patricia Roxburgh and B. Doger and P. Bajaj and J. Kefas and J.-.A. Scott and {Barba Joaqu{\'i}n}, Andr{\'e}s and C. Mueller and F. Triebel",

year = "2022",

month = sep,

day = "1",

doi = "10.1016/j.jtho.2022.07.681",

language = "English",

volume = "17",

pages = "S395",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier BV",

}

Forster, M, Krebs, M, Majem, M, Peguero, J, Clay, T, Felip, E, Iams, W, Roxburgh, P, Doger, B, Bajaj, P, Kefas, J, Scott, J-A, Barba Joaquín, A, Mueller, C & Triebel, F 2022, 'EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC', Journal of Thoracic Oncology, vol. 17, pp. S395. https://doi.org/10.1016/j.jtho.2022.07.681

TY - JOUR

T1 - EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

AU - Forster, M.

AU - Krebs, Matthew

AU - Majem, Margarita

AU - Peguero, J.

AU - Clay, Tonya

AU - Felip, E.

AU - Iams, Wade

AU - Roxburgh, Patricia

AU - Doger, B.

AU - Bajaj, P.

AU - Kefas, J.

AU - Scott, J.-.A.

AU - Barba Joaquín, Andrés

AU - Mueller, C.

AU - Triebel, F.

PY - 2022/9/1

Y1 - 2022/9/1

U2 - 10.1016/j.jtho.2022.07.681

DO - 10.1016/j.jtho.2022.07.681

M3 - Meeting Abstract

SN - 1556-0864

VL - 17

SP - S395

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

ER -